Diferencia entre revisiones de «HIV post-exposure prophylaxis»
| Línea 27: | Línea 27: | ||
^Prefered in pregnancy | ^Prefered in pregnancy | ||
National HIV/AIDS Clinicians' Consultation Center: 888-448-4911 | |||
==High Risk== | ==High Risk== | ||
Revisión del 04:49 24 nov 2012
Workup
- Td
- Hepatitis B PEP for non-vaccinated
- Hepatitis B immunoglobulin and/or vaccine
- Source labs
- Rapid HIV, hep pannel, RPR?
- Exposed labs
- Rapid HIV, hep pannel, RPR?
- Consider HIV PEP
- CBC, C7, LFTs, Icon if considering HIV PEP
^Currently no PEP for Hep C
HIV PEP
- ~79% transmission reduction
- Initiate ASAP (goal = 1-2 hours)
- >36 hours: normally deferred, unless particularly high risk
- Common side-effects = constitutional, gastrointestinal
Specific Regimens (CDC)
- Basic (2-Drug)
- Tenofovir-Emtricitabine 300mg/200mg (Truvada): 1 tab PO QD
- OR, Zidovudine-Lamivudine 300mg/150mg (Combivir)^: 1 tab PO BID
- Expanded (3-Drug)
- Ritonavir-Lopinavir 50mg/200mg(Kaletra): 2 tabs PO BID
- PLUS tenofovir-emtricitabine OR zidovudine-lamivudine
- Ritonavir-Lopinavir 50mg/200mg(Kaletra): 2 tabs PO BID
^Prefered in pregnancy
National HIV/AIDS Clinicians' Consultation Center: 888-448-4911
High Risk
Source
- Symptomatic HIV/AIDS
- Acute seroconversion
- High viral load
Exposure
- Deep injuries
- Visible blood on device
- Injuries sustained placing a catheter in a vein/artery
See Also
Source
8/07 DONALDSON
